Loading stock data…
ANIP
$81.86-2.05 (-2.44%)
Market ClosedLast close May 8
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ANI Pharmaceuticals, Inc. in the Healthcare sector is trading at $81.86. The stock is currently 18% below its 52-week high of $99.50, remaining 1.5% below its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why ANIP maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$81.86
Potential Downside
13.4%
Whystock Fair Value$70.87
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$110.63+35.1%
Range$90.00 – $124.00
Fundamentals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.14
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.49%
Volume
Today's trading volume
1.20M
Recent News
ANI Pharmaceuticals, Inc. (ANIP): A Small Cap Value Stock Capitalizing on Generic Drugs Opportunities
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is one of the best small-cap value stocks to buy. On April 20, ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) confirmed the Food and Drug Administration’s approval of Pimozide Tablets in 1 mg and 2 mg strengths. Following approval, the company has launched Pimozide tablets, a generic version of the reference listed drug (RLD) […]
3 Stocks Showing Powerful Earnings Acceleration This May
ANIP, CMI and SDRL stand out in May as earnings acceleration stocks, with rising EPS growth trends signaling potential share price momentum.
ANI Pharmaceuticals Q1 Earnings Call Highlights
ANI Pharmaceuticals (NASDAQ:ANIP) reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease company,” led by growth in Cortrophin Gel and ILUVIEN, contributions from a new intellectual property licen
ANI Pharmaceuticals (ANIP) shares jump after earnings beat and higher outlook
ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares surged 9.
ANI (ANIP) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.